Reversing Medications That Cause Bleeding

Size: px
Start display at page:

Download "Reversing Medications That Cause Bleeding"

Transcription

1 Reversing Medictions Tht Cuse Bleeding Dine M. Birnbumer, M.D., FACEP Professor of Medicine University of Cliforni, Los Angeles Senior Fculty Deprtment of Emergency Medicine Hrbor-UCLA Medicl Center The Agony nd The Ecstsy of Pltelets nd Clotting The Ecstsy We cn chnge how people clot We cn prevent strokes We cn prevent DVT nd PE We cn improve crdic outcomes in ACS The Agony nd The Ecstsy of Pltelets nd Clotting The Agony Vrible efficcy Nrrow therpeutic index Potentil drug / food interctions Need for monitoring Bleed risk Antidotes nd reversibility The Agony nd The Ecstsy of Pltelets nd Clotting We need better drugs nd guess wht! We hve them! But better HOW???? Newer is Better Right? Depends on wht color glsses you re looking through As crdiologist? As neurologist? As n emergency physicin? Or s ptient? Issues with the New Agents For emergency prctitioners Cn we mesure their ctivity if we need to? Cn we reverse their effects in cses of bleeding requiring emergency cre? 1

2 Will NOT cover Dltprin (Frgmin) Fondprinux (Arixtr) Aspirin Tried nd true Poisons pltelet for life of the pltelet 5-10 dys Cn reverse with (nd/or) Pltelet concentrte DDAVP ( µg/kg) Reversl in minutes Clopidigrel nd Prsugrel Thienopyridine derivtives Block ADP receptor on pltelet Cn be effectively combined with spirin in some cses Increses bleeding risk signficntly Therefore, in some cses the combintion overll is not worth the risk Clopidigrel nd Prsugrel Clopidigrel (Plvix ) vs. Prsugrel (Effient ) Prsugrel hs stronger ntipltelet effect In generl More effective thn clopidigrel More mjor bleeding events thn clopidigrel Clopidigrel nd Prsugrel Cn reverse with (nd/or) Pltelet concentrte (15-30 minutes) Mybe dd DDAVP ( µg/kg) Reversl in minutes 2

3 ETRINSIC Binds to ntithrombin Potentites inhibition of thrombin nd fctor (by 1000-fold) Hlf-life of minutes If stopped, hemostsis restored in 3-4 hr Reversed with protmine sulfte Dosing is 1 mg protmine per 100 units heprin given in lst 2-3 hours Usully mg effective Mximum dose 50 mg Hlf-life 10 minutes Reversl is immedite My cuse llergic rection Low Moleculr Weight Low dose vs. high dose hve differing hlf-lives Both, however, lst longer thn regulr unfrctionted IV heprin Low Moleculr Weight If stopped, hemostsis restored in hours Prtilly reversed by protmine sulfte 1 mg protmine per 100 units LMWH given in the lst 8 hours Mximum dose 50 mg Hlf-life 10 minutes; infusion my be needed Reversl, when effective, is immedite Vitmin K Antgonists 3

4 ETRINSIC Vit K Antgonists: Long experience with its use Blocks production of vitmin K dependent cogultion fctors (II, VII, I, ) Induces fctor deficiency stte Mens we my be ble to replce these fctors to reverse it Risk of mjor bleeding 0.5% per yer Risk of ICH is 0.2% per yer Vit K Antgonists: Risk of bleeding directly relted to height of INR Over 3.0, incidence doubles when compred to INR of Risk of bleeding increses with codministrtion of ntipltelet gents Elderly hve two-fold incresed risk of ICH Vit K Antgonists: Hemostsis fter cesstion: hours Reversl Vitmin K (dose depends on INR nd body wgt) IV: Reversl in hours PO: Reversl in 24 hours FFP lrge mounts needed my be prohibitory PCCs reversl is immedite Wht is PCC? Complex Concentrte Briplex, Octplex 4 fctors Profilnine, Bebulin 3 fctors Contin multiple fctors, including prothrombin Hve more prothrombin thn FFP Fctor Inhibitors The xbns 4

5 ETRINSIC Fctor Inhibitors Orl Fctor inhibitors relto (pproved 7/11/11) Eliquis (pproved 12/30/12) Cnnot mesure nticogulnt effect Fctor Inhibitors relto (pproved 7/11/11) Surgicl DVT prophylxis Stroke prevention in nonvlvulr AF DVT/PE tretment ACS coming down the pike? Eliquis (pproved 12/30/12) Stroke prevention in nonvlvulr AF Edoxbn - Lixin Fctor Inhibitors relto Hlf-life 5-13 hours Eliquis Hlf-life 9-14 hours Edoxbn - Lixin Hlf-life 9-10 hours Fctor Inhibitors Generl efficcy / sfety dt (so fr) Compred with LMWH (DVT prophylxis) Lower bleeding risk Similr efficcy Compred with wrfrin (stroke in AF) Noninferior to wrfrin Lower rte of bleeding (2.1 % vs 3%) Fctor Inhibitors Reversl in bleeding Cesstion of mediction will reverse nticogulnt effect How long it tkes depends on hlf-life All re too long in cses of serious bleeding Immedite reversl No ntidotes found to dte Fctor inhibitor ntidotes would be useful, being investigted but not vilble to dte 5

6 ETRINSIC Direct Thrombin Inhibitors Hirudin ws prototype (leech spit) Prdx (ppr. Oct 2010) Competitive, direct thrombin inhibitor Approved for Stroke prevention in A Fib (2010) DVT prophylxis fter surgery (ACS coming soon?) Hlf-life hours Prdx Benefits over wrfrin Anticogultion immedite No trnsient hypercogulble stte Does not require blood testing to monitor Miniml interctions with food/drugs Not recommended in renl filure or in ptients with impired heptic function Prdx For stroke prevention As effective s wrfrin Risk of mjor bleeding sme or less thn wrfrin (round 3%) Older ptients hd higher risk of bleeding Issues for emergencies Cnnot follow blood testing for nticogultion effect (non-liner effect) Cogultion studies re elevted, but do not correlte with bleeding risk (Note: These rtes were in trils; we ll see wht hppens in the rel world ) 6

7 Issues for emergencies Tretment of bleeding Supportive cre prbcs, IV fluids, stopping bleeding by direct mens Activting thrombin Removing dbigtrn Not highly protein bound 4 hours of dilysis removes 68% of dbigtrn Direct Thrombin (II)Inhibitors Issues for emergencies Tretment of bleeding Activting thrombin My be impossible FFP hs miniml prothrombin not likely useful PCCs my be useful but poorly studied to dte rvii not dequtely studied nd unlikely useful Not useful: Cryoprecipitte, protmine, DDAVP, trnexmic cid, minocproic cid Time to hemostsis fter stopping tking mediction Antidote Time to reversl 3-4 hr Protmine sulfte Immedite LMW hr Protmine (prtil) Immedite Pentscchrides Fond: hr Idrpr: 5-15k Recomb VII Vit K Antg : hr Vit K IV Vit K orl PCCs Orl thrombin nd fctor inhibitors Usully within 12 hr Recomb fct Thrombin???? Immedite thrombin genertion hr 24 hr Immedite Unknown Thnk You For Your Attention! Any Questions? Aspirin 5-10 dys DDAVP, pltelets minutes Clopidogrel Prsugrel 1-2 dys Pltelets, mybe DDAVP minutes 7

The Brave New (Anticoagulant) World

The Brave New (Anticoagulant) World The Brave New (Anticoagulant) World Diane M. Birnbaumer, M.D., FACEP Emeritus Professor of Medicine University of California, Los Angeles Senior Clinical Educator Department of Emergency Medicine Harbor-UCLA

More information

INITIATION OF THERAPY Patient-specific considerations for initiation of apixaban therapy include the following:

INITIATION OF THERAPY Patient-specific considerations for initiation of apixaban therapy include the following: UNC HEALTH CARE GUIDELINE Mngement of Apixn in Adults Apixn (Eliquis ) is n orl nticogulnt tht cts s fctor X inhiitor. It is pproved y the FDA for the prevention of stroke nd systemic emolism in ptients

More information

INITIATION OF THERAPY Patient-specific considerations for initiation of rivaroxaban therapy include the following:

INITIATION OF THERAPY Patient-specific considerations for initiation of rivaroxaban therapy include the following: UNC HEALTH CARE GUIDELINE Mngement of Rivroxn in Adults Rivroxn (Xrelto ) is n orl nticogulnt tht cts s fctor X inhiitor. It is pproved y the FDA for the following indictions: Prevention of stroke nd systemic

More information

TABLE 1. Initial Rivaroxaban Dosing Indication Renal Function a (CrCL ml/min) Recommended Dose b

TABLE 1. Initial Rivaroxaban Dosing Indication Renal Function a (CrCL ml/min) Recommended Dose b U N C H E A L T H C A R E G U I D E L I N E Mngement of Rivroxn in Adults Rivroxn (Xrelto ) is n orl nticogulnt tht cts s fctor X inhiitor. It is pproved y the FDA s n lterntive to wrfrin for the prevention

More information

How To Know What A Pressure Ulcer Is

How To Know What A Pressure Ulcer Is Pressure Ulcers ecourse: Module 2 Quiz I 1. Blck, brown or tn tissue tht dheres firmly to the wound bed or ulcer edges nd my be either firmer or softer thn surrounding tissue is:. Eschr b. Slough c. Grnultion

More information

Xabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center

Xabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center Xabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center DISCLOSURES No relevant financial disclosures I will

More information

Reversal of Antiplatelet and Anticoagulant Therapy: What You Need To Know. Ronald Walsh, MD Chief Medical Officer Community Blood Services

Reversal of Antiplatelet and Anticoagulant Therapy: What You Need To Know. Ronald Walsh, MD Chief Medical Officer Community Blood Services Reversal of Antiplatelet and Anticoagulant Therapy: What You Need To Know Ronald Walsh, MD Chief Medical Officer Community Blood Services HEMOSTATIC PROCESS Initiation and formation of the platelet plug

More information

Making Sense of the Newer Anticoagulants

Making Sense of the Newer Anticoagulants Making Sense of the Newer Anticoagulants Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center I M FROM ARIZONA! DISCLOSURES No relevant

More information

Anticoagulation and Reversal

Anticoagulation and Reversal Anticoagulation and Reversal John Howard, PharmD, BCPS Clinical Pharmacist Internal Medicine Affiliate Associate Clinical Professor South Carolina College of Pharmacy Disclosures I have no Financial, Industry,

More information

Active & Retiree Plan: Trustees of the Milwaukee Roofers Health Fund Coverage Period: 06/01/2015-05/31/2016 Summary of Benefits and Coverage:

Active & Retiree Plan: Trustees of the Milwaukee Roofers Health Fund Coverage Period: 06/01/2015-05/31/2016 Summary of Benefits and Coverage: Summry of Benefits nd Coverge: Wht this Pln Covers & Wht it Costs Coverge for: Single & Fmily Pln Type: NPOS This is only summry. If you wnt more detil bout your coverge nd costs, you cn get the complete

More information

High Risk Emergency Medicine

High Risk Emergency Medicine High Risk Emergency Medicine Minor Head Injuries in Patients on Oral Anticoagulants David Thompson, MD, MPH Assistant Professor Department of Emergency Medicine No relevant financial relationships to disclose

More information

Polynomial Functions. Polynomial functions in one variable can be written in expanded form as ( )

Polynomial Functions. Polynomial functions in one variable can be written in expanded form as ( ) Polynomil Functions Polynomil functions in one vrible cn be written in expnded form s n n 1 n 2 2 f x = x + x + x + + x + x+ n n 1 n 2 2 1 0 Exmples of polynomils in expnded form re nd 3 8 7 4 = 5 4 +

More information

Treatment Spring Late Summer Fall 0.10 5.56 3.85 0.61 6.97 3.01 1.91 3.01 2.13 2.99 5.33 2.50 1.06 3.53 6.10 Mean = 1.33 Mean = 4.88 Mean = 3.

Treatment Spring Late Summer Fall 0.10 5.56 3.85 0.61 6.97 3.01 1.91 3.01 2.13 2.99 5.33 2.50 1.06 3.53 6.10 Mean = 1.33 Mean = 4.88 Mean = 3. The nlysis of vrince (ANOVA) Although the t-test is one of the most commonly used sttisticl hypothesis tests, it hs limittions. The mjor limittion is tht the t-test cn be used to compre the mens of only

More information

Stop the Bleeding: Management of Drug-induced Coagulopathy. Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery

Stop the Bleeding: Management of Drug-induced Coagulopathy. Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery Stop the Bleeding: Management of Drug-induced Coagulopathy Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery Objectives Discuss contemporary management of warfarin reversal in patients

More information

Health insurance marketplace What to expect in 2014

Health insurance marketplace What to expect in 2014 Helth insurnce mrketplce Wht to expect in 2014 33096VAEENBVA 06/13 The bsics of the mrketplce As prt of the Affordble Cre Act (ACA or helth cre reform lw), strting in 2014 ALL Americns must hve minimum

More information

Health insurance exchanges What to expect in 2014

Health insurance exchanges What to expect in 2014 Helth insurnce exchnges Wht to expect in 2014 33096CAEENABC 02/13 The bsics of exchnges As prt of the Affordble Cre Act (ACA or helth cre reform lw), strting in 2014 ALL Americns must hve minimum mount

More information

Utilization of Smoking Cessation Benefits in Medicaid Managed Care, 2009-2013

Utilization of Smoking Cessation Benefits in Medicaid Managed Care, 2009-2013 Utiliztion of Smoking Cesstion Benefits in Medicid Mnged Cre, 2009-2013 Office of Qulity nd Ptient Sfety New York Stte Deprtment of Helth Jnury 2015 Introduction According to the New York Stte Tocco Control

More information

New Anticoagulants: What to Use What to Avoid

New Anticoagulants: What to Use What to Avoid New Anticoagulants: What to Use What to Avoid Bruce Davidson, MD, MPH Clinical Professor of Medicine Pulmonary and Critical Care Medicine Division University of Washington School of Medicine Seattle USA

More information

Humana Critical Illness/Cancer

Humana Critical Illness/Cancer Humn Criticl Illness/Cncer Criticl illness/cncer voluntry coverges py benefits however you wnt With our criticl illness nd cncer plns, you'll receive benefit fter serious illness or condition such s hert

More information

3/3/2015. Patrick Cobb, MD, FACP March 2015

3/3/2015. Patrick Cobb, MD, FACP March 2015 Patrick Cobb, MD, FACP March 2015 I, Patrick Cobb, MD, DO NOT have a financial interest/arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict

More information

Econ 4721 Money and Banking Problem Set 2 Answer Key

Econ 4721 Money and Banking Problem Set 2 Answer Key Econ 472 Money nd Bnking Problem Set 2 Answer Key Problem (35 points) Consider n overlpping genertions model in which consumers live for two periods. The number of people born in ech genertion grows in

More information

Target: 10 mg/day within several days Schizophrenia in adolescents (2.1)

Target: 10 mg/day within several days Schizophrenia in adolescents (2.1) HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ZYPREXA sfely nd effectively. See full prescribing informtion for ZYPREXA. ZYPREXA (olnzpine) Tblet

More information

Hematopoietic stem cell transplantation

Hematopoietic stem cell transplantation Online Clinicl Investigtions Improved outcomes for stem cell trnsplnt recipients requiring peditric intensive cre Rnjit S. Chim, MD; Rodney C. Dniels, MD; Mi-Ok Kim, PhD; Dndn Li, MS; Derek S. Wheeler,

More information

Quick Reference Guide: One-time Account Update

Quick Reference Guide: One-time Account Update Quick Reference Guide: One-time Account Updte How to complete The Quick Reference Guide shows wht existing SingPss users need to do when logging in to the enhnced SingPss service for the first time. 1)

More information

New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012

New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012 New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation Joy Wahawisan, Pharm.D., BCPS April 25, 2012 Stroke in Atrial Fibrillation % Stroke 1991;22:983. Age Range (years) CHADS 2 Risk

More information

Target: 10 mg/day within several days Schizophrenia in adolescents (2.1) Oral: Start at 2.5-5 mg once daily; Target: 10 mg/day

Target: 10 mg/day within several days Schizophrenia in adolescents (2.1) Oral: Start at 2.5-5 mg once daily; Target: 10 mg/day HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ZYPREXA sfely nd effectively. See full prescribing informtion for ZYPREXA. ZYPREXA (olnzpine) Tblet

More information

Objective: Erectile dysfunction and depression are highly associated. Previous studies have shown benefits of phosphodiesterase-5

Objective: Erectile dysfunction and depression are highly associated. Previous studies have shown benefits of phosphodiesterase-5 Article Efficcy nd Tolerbility of Vrdenfil in Men With Mild Depression nd Erectile Dysfunction: The Depression-Relted Improvement With Vrdenfil for Erectile Response Study Rymond Rosen, Ph.D. Ridwn Shbsigh,

More information

Warnings and Precautions Never Share a Humalog KwikPen, Cartridge, Reusable Pen Compatible with Lilly 3 ml Cartridges, or Syringe Between

Warnings and Precautions Never Share a Humalog KwikPen, Cartridge, Reusable Pen Compatible with Lilly 3 ml Cartridges, or Syringe Between 1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use HUMALOG sfely nd effectively. See full prescriing informtion for HUMALOG. HUMALOG (insulin lispro

More information

The Role of the Newer Anticoagulants

The Role of the Newer Anticoagulants The Role of the Newer Anticoagulants WARFARIN = Coumadin DAGIBATRAN = Pradaxa RIVAROXABAN = Xarelto APIXABAN = Eliquis INDICATION DABIGATRAN (Pradaxa) RIVAROXABAN (Xarelto) APIXABAN (Eliquis) Stroke prevention

More information

Anthem Blue Cross Life and Health Insurance Company University of Southern California Custom Premier PPO 800/20%/20%

Anthem Blue Cross Life and Health Insurance Company University of Southern California Custom Premier PPO 800/20%/20% Anthem Blue Cross Life nd Helth Insurnce Compny University of Southern Cliforni Custom Premier 800/20%/20% Summry of Benefits nd Coverge: Wht this Pln Covers & Wht it Costs Coverge Period: 01/01/2015-12/31/2015

More information

Or more simply put, when adding or subtracting quantities, their uncertainties add.

Or more simply put, when adding or subtracting quantities, their uncertainties add. Propgtion of Uncertint through Mthemticl Opertions Since the untit of interest in n eperiment is rrel otined mesuring tht untit directl, we must understnd how error propgtes when mthemticl opertions re

More information

New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis

New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ET Departments of Gastroenterology and Hepatology,

More information

AJP in Advance. Published May 2, 2011 (doi: 10.1176/appi.ajp.2011.10111645) Article

AJP in Advance. Published May 2, 2011 (doi: 10.1176/appi.ajp.2011.10111645) Article AJP in Advnce. Published My 2, 2011 (doi: 10.1176/ppi.jp.2011.10111645) Article Combining Medictions to Enhnce Depression Outcomes (CO-MED): Acute nd Long-Term Outcomes of Single-Blind Rndomized Study

More information

5/21/2012. Perioperative Use Issues. On admission: During hospitalization:

5/21/2012. Perioperative Use Issues. On admission: During hospitalization: Dabigatran and Rivaroxaban: Challenges in the Perioperative Setting Claudia Swenson, Pharm.D., CDE, BC-ADM, FASHP Central Washington Hospital Wenatchee, WA claudia.swenson@cwhs.com Dabigatran and Rivaroxaban:

More information

Critical Bleeding Reversal Protocol

Critical Bleeding Reversal Protocol Critical Bleeding Reversal Protocol Coagulopathy, either drug related or multifactorial, is a major contributing factor to bleeding related mortality in a variety of clinical settings. Standard therapy

More information

Graphs on Logarithmic and Semilogarithmic Paper

Graphs on Logarithmic and Semilogarithmic Paper 0CH_PHClter_TMSETE_ 3//00 :3 PM Pge Grphs on Logrithmic nd Semilogrithmic Pper OBJECTIVES When ou hve completed this chpter, ou should be ble to: Mke grphs on logrithmic nd semilogrithmic pper. Grph empiricl

More information

LAMC Reversal Agent Guideline for Anticoagulants 2013. Time to resolution of hemostasis (hrs) Therapeutic Options

LAMC Reversal Agent Guideline for Anticoagulants 2013. Time to resolution of hemostasis (hrs) Therapeutic Options LAMC Reversal Agent Guideline for Anticoagulants 2013 Medication resolution of hemostasis (hrs) Intervention Administration Instructions Heparin 3-4 Protamine 1mg IV for every 100 units of heparin Slow

More information

PROF. BOYAN KOSTADINOV NEW YORK CITY COLLEGE OF TECHNOLOGY, CUNY

PROF. BOYAN KOSTADINOV NEW YORK CITY COLLEGE OF TECHNOLOGY, CUNY MAT 0630 INTERNET RESOURCES, REVIEW OF CONCEPTS AND COMMON MISTAKES PROF. BOYAN KOSTADINOV NEW YORK CITY COLLEGE OF TECHNOLOGY, CUNY Contents 1. ACT Compss Prctice Tests 1 2. Common Mistkes 2 3. Distributive

More information

Epilepsy & Behavior 15 (2009) 56 65. Contents lists available at ScienceDirect. Epilepsy & Behavior. journal homepage: www.elsevier.

Epilepsy & Behavior 15 (2009) 56 65. Contents lists available at ScienceDirect. Epilepsy & Behavior. journal homepage: www.elsevier. Epilepsy & Behvior 15 (2009) 56 65 Contents lists vilble t ScienceDirect Epilepsy & Behvior journl homepge: www.elsevier.com/locte/yebeh Drug tretment of epilepsy: Options nd limittions Dieter Schmidt

More information

Health insurance exchanges What to expect in 2014

Health insurance exchanges What to expect in 2014 Helth insurnce exchnges Wht to expect in 2014 33096CAEENABC 11/12 The bsics of exchnges As prt of the Affordble Cre Act (ACA or helth cre reform lw), strting in 2014 ALL Americns must hve minimum mount

More information

Schedule of benefits Benefits Preferred Advantage Basic Enhanced C

Schedule of benefits Benefits Preferred Advantage Basic Enhanced C Schedule of enefits Benefits Preferred Advntge Bsic Enhnced C Wrd entitlement Stndrd room in privte hospitl or privte medicl institution Restructured hospitl for wrd clss A nd elow Restructured hospitl

More information

Small Businesses Decisions to Offer Health Insurance to Employees

Small Businesses Decisions to Offer Health Insurance to Employees Smll Businesses Decisions to Offer Helth Insurnce to Employees Ctherine McLughlin nd Adm Swinurn, June 2014 Employer-sponsored helth insurnce (ESI) is the dominnt source of coverge for nonelderly dults

More information

Warm-up for Differential Calculus

Warm-up for Differential Calculus Summer Assignment Wrm-up for Differentil Clculus Who should complete this pcket? Students who hve completed Functions or Honors Functions nd will be tking Differentil Clculus in the fll of 015. Due Dte:

More information

Impact of new (direct) oral anticoagulants in patient blood management

Impact of new (direct) oral anticoagulants in patient blood management Impact of new (direct) oral anticoagulants in patient blood management Yulia Lin, MD, FRCPC, CTBS Transfusion Medicine & Hematology, Sunnybrook Health Sciences Centre Dept of Laboratory Medicine & Pathobiology,

More information

Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation

Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 29,

More information

COMPARISON OF SOME METHODS TO FIT A MULTIPLICATIVE TARIFF STRUCTURE TO OBSERVED RISK DATA BY B. AJNE. Skandza, Stockholm ABSTRACT

COMPARISON OF SOME METHODS TO FIT A MULTIPLICATIVE TARIFF STRUCTURE TO OBSERVED RISK DATA BY B. AJNE. Skandza, Stockholm ABSTRACT COMPARISON OF SOME METHODS TO FIT A MULTIPLICATIVE TARIFF STRUCTURE TO OBSERVED RISK DATA BY B. AJNE Skndz, Stockholm ABSTRACT Three methods for fitting multiplictive models to observed, cross-clssified

More information

How To Study The Effects Of Music Composition On Children

How To Study The Effects Of Music Composition On Children C-crcs Cognitive - Counselling Reserch & Conference Services (eissn: 2301-2358) Volume I Effects of Music Composition Intervention on Elementry School Children b M. Hogenes, B. Vn Oers, R. F. W. Diekstr,

More information

baby on the way, quit today

baby on the way, quit today for mums-to-be bby on the wy, quit tody WHAT YOU NEED TO KNOW bout smoking nd pregnncy uitting smoking is the best thing you cn do for your bby We know tht it cn be difficult to quit smoking. But we lso

More information

Malignant Pleural Mesothelioma (MPM) treatment with ALIMTA therapy

Malignant Pleural Mesothelioma (MPM) treatment with ALIMTA therapy YOUR LIFE. Mlignnt Pleurl Mesotheliom (MPM) tretment with ALIMTA therpy ALIMTA is tretment for mlignnt pleurl mesotheliom (MPM), which is cncer tht ffects the inside lining of the chest cvity. ALIMTA is

More information

Anticoagulation Essentials! Parenteral and Oral!

Anticoagulation Essentials! Parenteral and Oral! Anticoagulation Essentials! Parenteral and Oral! Anti-Xa and Anti-IIa! Parenteral Anticoagulants! Heparin family (indirect anti-xa and anti-iia):! UFH! LMWH (enoxaparin, fondaparinux)! Direct thrombin

More information

EXPERIMENTAL AND THERAPEUTIC MEDICINE 8: 1191-1196, 2014

EXPERIMENTAL AND THERAPEUTIC MEDICINE 8: 1191-1196, 2014 EXPERIMENTAL AND THERAPEUTIC MEDICINE 8: 1191-1196, 2014 Comprison of continuous subcutneous insulin infusion nd insulin glrgine-bsed multiple dily insulin sprt injections with preferentil djustment of

More information

Section 7-4 Translation of Axes

Section 7-4 Translation of Axes 62 7 ADDITIONAL TOPICS IN ANALYTIC GEOMETRY Section 7-4 Trnsltion of Aes Trnsltion of Aes Stndrd Equtions of Trnslted Conics Grphing Equtions of the Form A 2 C 2 D E F 0 Finding Equtions of Conics In the

More information

274 Chapter 13. Chapter 13

274 Chapter 13. Chapter 13 74 hpter 3 hpter 3 3. () ounts will be obtined from the smples so th problem bout compring proportions. (b) h n observtionl study compring rndom smples selected from two independent popultions. 3. () cores

More information

Update on Antiplatelets and anticoagulants. Outlines. Antiplatelets and Anticoagulants 1/23/2013. Timir Paul, MD, PhD

Update on Antiplatelets and anticoagulants. Outlines. Antiplatelets and Anticoagulants 1/23/2013. Timir Paul, MD, PhD Update on Antiplatelets and anticoagulants Timir Paul, MD, PhD Antiplatelets Indications Doses Long term use (beyond 12 months) ASA and combination use of NSAIDS ASA resistance Plavix resistance Plavix

More information

Answer, Key Homework 10 David McIntyre 1

Answer, Key Homework 10 David McIntyre 1 Answer, Key Homework 10 Dvid McIntyre 1 This print-out should hve 22 questions, check tht it is complete. Multiple-choice questions my continue on the next column or pge: find ll choices efore mking your

More information

3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.

3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin. To Clot or Not What s New In Anticoagulation? Anita Ralstin, MS CNS CNP 1 Clotting Cascade 2 Anticoagulant drug targets Heparin XI VIII IX V X VII LMWH II Warfarin Fibrin clot 1 Who Needs Anticoagulation

More information

48 th Annual Meeting. Non-VKA Oral Anticoagulants: Prevention & Treatment of Bleeding. Terminology. Disclosure. Public Health Impact.

48 th Annual Meeting. Non-VKA Oral Anticoagulants: Prevention & Treatment of Bleeding. Terminology. Disclosure. Public Health Impact. 48 th Annual Meeting Terminology Non-VKA Oral Anticoagulants: Prevention & Treatment of Bleeding Stacy A. Voils, PharmD, MS, BCPS Navigating the Oceans of Opportunity Target-specific oral anticoagulants

More information

Anticoagulant Reversal

Anticoagulant Reversal No Conflicts of Interest to Report Anticoagulant Reversal Matthew Bondi Pharm.D., BCPS March 14, 2015 Matthew Bondi Pharm.D., BCPS. Clinical Pharmacist Sparrow Hospital Matthew.bondi@sparrow.org Ph. 517.364.2031

More information

Operations with Polynomials

Operations with Polynomials 38 Chpter P Prerequisites P.4 Opertions with Polynomils Wht you should lern: Write polynomils in stndrd form nd identify the leding coefficients nd degrees of polynomils Add nd subtrct polynomils Multiply

More information

Rate and Activation Energy of the Iodination of Acetone

Rate and Activation Energy of the Iodination of Acetone nd Activtion Energ of the Iodintion of Acetone rl N. eer Dte of Eperiment: //00 Florence F. Ls (prtner) Abstrct: The rte, rte lw nd ctivtion energ of the iodintion of cetone re detered b observing the

More information

P.3 Polynomials and Factoring. P.3 an 1. Polynomial STUDY TIP. Example 1 Writing Polynomials in Standard Form. What you should learn

P.3 Polynomials and Factoring. P.3 an 1. Polynomial STUDY TIP. Example 1 Writing Polynomials in Standard Form. What you should learn 33337_0P03.qp 2/27/06 24 9:3 AM Chpter P Pge 24 Prerequisites P.3 Polynomils nd Fctoring Wht you should lern Polynomils An lgeric epression is collection of vriles nd rel numers. The most common type of

More information

Cardiology Update 2014

Cardiology Update 2014 Cardiology Update 2014 Update on the Novel Oral Anticoagulants (NOACS) Raymond Kawasaki, MD AMG Cardiology December 6, 2014 Disclosures I have no disclosures relevant to this presentation Contents I. The

More information

OHIO CRIMINAL SENTENCING COMMISSION 65 South Front Street Second Floor Columbus 43215 Telephone: (614) 387-9305 Fax: (614) 387-9309

OHIO CRIMINAL SENTENCING COMMISSION 65 South Front Street Second Floor Columbus 43215 Telephone: (614) 387-9305 Fax: (614) 387-9309 OHIO CRIMINAL SENTENCING COMMISSION 65 South Front Street Second Floor Columus 43215 Telephone: (614) 387-9305 Fx: (614) 387-9309 TRAFFIC SENTENCING TABLES: DUS, OVI, & VEHICULAR HOMICIDES/ASSAULTS By

More information

Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab

Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 28, 2015 2:30 pm I have no disclosures. Stroke risk reduction in

More information

Math 135 Circles and Completing the Square Examples

Math 135 Circles and Completing the Square Examples Mth 135 Circles nd Completing the Squre Exmples A perfect squre is number such tht = b 2 for some rel number b. Some exmples of perfect squres re 4 = 2 2, 16 = 4 2, 169 = 13 2. We wish to hve method for

More information

Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical

Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Center A.Fib affects 2.2 million Americans. The lifetime

More information

Multiple Sclerosis at AAN 2010: Safety, Switching, and Emerging Therapies

Multiple Sclerosis at AAN 2010: Safety, Switching, and Emerging Therapies Multiple Sclerosis t AAN 2010: Sfety, Switching, nd Emerging Therpies Mrk S. Freedmn, MSc, MD Professor of Neurology, University of Ottw, Ottw, Ontrio, Cnd; Director, Multiple Sclerosis Reserch Unit, The

More information

See 17 for PATIENT COUNSELING INFORMATION. Revised: 11/2013

See 17 for PATIENT COUNSELING INFORMATION. Revised: 11/2013 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use BOOSTRIX sfely nd effectively. See full prescribing informtion for BOOSTRIX. BOOSTRIX (Tetnus Toxoid,

More information

Review of Newer Antiplatelets, Antithrombotics and Reversal

Review of Newer Antiplatelets, Antithrombotics and Reversal Review of Newer Antiplatelets, Antithrombotics and Reversal Ravi Sarode, MD Professor of Pathology Chief of Pathology and Medical Director of Clinical Laboratory Services Director, Transfusion Medicine

More information

Reversing the New Anticoagulants

Reversing the New Anticoagulants Reversing the New Anticoagulants Disclosure Susan C. Lambe, MD Assistant Clinical Professor Department of Emergency Medicine University of California, San Francisco Roadmap for today 1 Roadmap for today

More information

Speaker Disclosure. Outline. Pharmacist Objectives. Patient Case. Outline 9/4/2014

Speaker Disclosure. Outline. Pharmacist Objectives. Patient Case. Outline 9/4/2014 Speaker Disclosure Matthew K. Pitlick, Pharm.D., BCPS St. Louis College of Pharmacy/VA St. Louis HCS mpitlick@stlcop.edu Matthew K. Pitlick, Pharm.D., BCPS declares no conflicts of interest, real or apparent,

More information

Session 3 Topics. Argatroban. Argatroban. Drug Use and Adverse Effects. Laboratory Monitoring of Anticoagulant Therapy

Session 3 Topics. Argatroban. Argatroban. Drug Use and Adverse Effects. Laboratory Monitoring of Anticoagulant Therapy ~~Marshfield Labs Presents~~ Laboratory Monitoring of Anticoagulant Therapy Session 3 of 4 Michael J. Sanfelippo, M.S. Technical Director, Coagulation Services Session 3 Topics Direct Thrombin Inhibitors:

More information

How To Treat Aneuricaagulation

How To Treat Aneuricaagulation Speaker Introduction Jessica Wilhoite, PharmD, BCACP Doctor of Pharmacy: Purdue University Postgraduate Residency Training: PGY1 Pharmacy Practice St. Vincent Hospital PGY2 Ambulatory Care St. Vincent

More information

Pure C4. Revision Notes

Pure C4. Revision Notes Pure C4 Revision Notes Mrch 0 Contents Core 4 Alger Prtil frctions Coordinte Geometry 5 Prmetric equtions 5 Conversion from prmetric to Crtesin form 6 Are under curve given prmetriclly 7 Sequences nd

More information

What we all Needs to Know about New and Old Anticoagulant and Antiplatelet Drugs. None related to this presentation 11/22/2012

What we all Needs to Know about New and Old Anticoagulant and Antiplatelet Drugs. None related to this presentation 11/22/2012 What we all Needs to Know about New and Old Anticoagulant and Antiplatelet Drugs Marvin A Wayne, MD, FACEP, FAAEM Associate Clinical Professor University of Washington, EMS Medical Director Whatcom County,

More information

Factoring Polynomials

Factoring Polynomials Fctoring Polynomils Some definitions (not necessrily ll for secondry school mthemtics): A polynomil is the sum of one or more terms, in which ech term consists of product of constnt nd one or more vribles

More information

DlNBVRGH + Sickness Absence Monitoring Report. Executive of the Council. Purpose of report

DlNBVRGH + Sickness Absence Monitoring Report. Executive of the Council. Purpose of report DlNBVRGH + + THE CITY OF EDINBURGH COUNCIL Sickness Absence Monitoring Report Executive of the Council 8fh My 4 I.I...3 Purpose of report This report quntifies the mount of working time lost s result of

More information

Physics 43 Homework Set 9 Chapter 40 Key

Physics 43 Homework Set 9 Chapter 40 Key Physics 43 Homework Set 9 Chpter 4 Key. The wve function for n electron tht is confined to x nm is. Find the normliztion constnt. b. Wht is the probbility of finding the electron in. nm-wide region t x

More information

FAULT TREES AND RELIABILITY BLOCK DIAGRAMS. Harry G. Kwatny. Department of Mechanical Engineering & Mechanics Drexel University

FAULT TREES AND RELIABILITY BLOCK DIAGRAMS. Harry G. Kwatny. Department of Mechanical Engineering & Mechanics Drexel University SYSTEM FAULT AND Hrry G. Kwtny Deprtment of Mechnicl Engineering & Mechnics Drexel University OUTLINE SYSTEM RBD Definition RBDs nd Fult Trees System Structure Structure Functions Pths nd Cutsets Reliility

More information

Helicopter Theme and Variations

Helicopter Theme and Variations Helicopter Theme nd Vritions Or, Some Experimentl Designs Employing Pper Helicopters Some possible explntory vribles re: Who drops the helicopter The length of the rotor bldes The height from which the

More information

How To Increase Warfarin

How To Increase Warfarin Anticoagulants for venous thromboembolic disease- Optimizing the old, ushering in the new. Daniel A. Forman, DO RPS Hematology Oncology daniel.forman@readinghealth.org 610 509 5067 cell RHS Anticoagulation

More information

New Oral AntiCoagulants (NOAC) in 2015

New Oral AntiCoagulants (NOAC) in 2015 New Oral AntiCoagulants (NOAC) in 2015 William R. Hiatt, MD Professor of Medicine and Cardiology University of Colorado School of Medicine President CPC Clinical Research Disclosures Received research

More information

23/06/2014. Implications for the Gastroenterologist. No financial interests I am not a hematologist

23/06/2014. Implications for the Gastroenterologist. No financial interests I am not a hematologist Implications for the Gastroenterologist Dr. Daniel Sadowski Royal Alexandra Hospital Edmonton, Ab. No financial interests I am not a hematologist 65 y.o. male referred for iron deficiency anemia (FIT positive)

More information

ADVATE [Antihemophilic Factor (Recombinant)] Lyophilized Powder for Reconstitution for Intravenous Injection Initial U.S.

ADVATE [Antihemophilic Factor (Recombinant)] Lyophilized Powder for Reconstitution for Intravenous Injection Initial U.S. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ADVATE sfely nd effectively. See full prescribing informtion for ADVATE. ADVATE [Antihemophilic Fctor

More information

Use Geometry Expressions to create a more complex locus of points. Find evidence for equivalence using Geometry Expressions.

Use Geometry Expressions to create a more complex locus of points. Find evidence for equivalence using Geometry Expressions. Lerning Objectives Loci nd Conics Lesson 3: The Ellipse Level: Preclculus Time required: 120 minutes In this lesson, students will generlize their knowledge of the circle to the ellipse. The prmetric nd

More information

GUIDELINES IN ANTIPLATELET AND ANTICOAGULATION RX IN CARDIAC SURGERY

GUIDELINES IN ANTIPLATELET AND ANTICOAGULATION RX IN CARDIAC SURGERY BLOOD CONSERVATION STRATEGIES IN CARDIAC SURGERY: MORE IS BETTER GUIDELINES IN ANTIPLATELET AND ANTICOAGULATION RX IN CARDIAC SURGERY DIMITRIOS V. AVGERINOS MD, PhD, FACS, FACC Department of Cardiac Surgery,

More information

Appendix D: Completing the Square and the Quadratic Formula. In Appendix A, two special cases of expanding brackets were considered:

Appendix D: Completing the Square and the Quadratic Formula. In Appendix A, two special cases of expanding brackets were considered: Appendi D: Completing the Squre nd the Qudrtic Formul Fctoring qudrtic epressions such s: + 6 + 8 ws one of the topics introduced in Appendi C. Fctoring qudrtic epressions is useful skill tht cn help you

More information

Exponential and Logarithmic Functions

Exponential and Logarithmic Functions Nme Chpter Eponentil nd Logrithmic Functions Section. Eponentil Functions nd Their Grphs Objective: In this lesson ou lerned how to recognize, evlute, nd grph eponentil functions. Importnt Vocbulr Define

More information

Advanced Issues in Peri-Operative VTE Prevention

Advanced Issues in Peri-Operative VTE Prevention Advanced Issues in Peri-Operative VTE Prevention Michael-Anthony (M-A) Williams, M.D. Consultant Physician Centura Medical Consultants September 27th, 2012 Main Topics 1. The perils of the early mover-

More information

Vendor Rating for Service Desk Selection

Vendor Rating for Service Desk Selection Vendor Presented By DATE Using the scores of 0, 1, 2, or 3, plese rte the vendor's presenttion on how well they demonstrted the functionl requirements in the res below. Also consider how efficient nd functionl

More information

Advances in An+coagula+on

Advances in An+coagula+on Advances in An+coagula+on Laurajo Ryan PharmD, MSc, BCPS, CDE Clinical Associate Professor The University of Texas at Aus+n College of Pharmacy UTHSCSA School of Medicine Pharmcotherapy Research Educa+on

More information

Comparison between New Oral Anticoagulants and Warfarin

Comparison between New Oral Anticoagulants and Warfarin Comparison between New Oral Anticoagulants and Warfarin Warfarin was the mainstay of oral anticoagulant therapy until the recent discovery of more precise targets for therapy. In recent years, several

More information

Many national organizations

Many national organizations SYMPOSIUM Primry-cre setting Implementtion of drug therpy monitoring clinic in primry-cre setting JILLMARIE K. YANCHICK Mny ntionl orgniztions hve identified the optiml mngement of chronic disese sttes

More information

Your duty, however, does not require disclosure of matter:

Your duty, however, does not require disclosure of matter: Your Duty of Disclosure Before you enter into contrct of generl insurnce with n insurer, you hve duty, under the Insurnce Contrcts Act 1984 (Cth), to disclose to the insurer every mtter tht you know, or

More information

How does warfarin work? We know itʼs a vitamin k antagonist, but what does that mean? What's really getting antagonized?

How does warfarin work? We know itʼs a vitamin k antagonist, but what does that mean? What's really getting antagonized? Anticoagulation reversal Vitamin K antagonists and New Oral Anticoagulants Robert Orman, MD Warfarin How does warfarin work? We know itʼs a vitamin k antagonist, but what does that mean? What's really

More information

Program Objectives. Why Use Anticoagulants? 6/5/2014

Program Objectives. Why Use Anticoagulants? 6/5/2014 Larry Reis RPh CGP FASCP Prepared June 2014 for NADONA REIS RXCARE CONSULTING Reisrxcare@comcast.net 1 Program Objectives Discuss complications of current anticoagulant Rx Identify risks of using anticoagulants

More information

The sickle cell diseases (SCDs) affect approximately

The sickle cell diseases (SCDs) affect approximately o r i g i n l c o m m u n i c t i o n Pin Mngement in Adults With Sickle Cell Disese in Medicl Center Emergency Deprtment Lwrence R. Solomon, MD Previous Presenttion: This pper ws presented in prt in bstrct

More information

DVT/PE Management with Rivaroxaban (Xarelto)

DVT/PE Management with Rivaroxaban (Xarelto) DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular

More information

Traditional anticoagulants

Traditional anticoagulants TEGH Family Practice Clinic Day April 4, 03 Use of Anticoagulants in 03: What s New (and What Isn t) Bill Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University

More information

Dr Gordon Royle Haematologist, Middlemore Hospital

Dr Gordon Royle Haematologist, Middlemore Hospital The New Oral Anticoagulants (NOACs) Dr Gordon Royle Haematologist, Middlemore Hospital Disclaimers Boehringer-Ingelheim Bayer Sanofi Douglas Pharmaceuticals Preventing disasters: lessons learned A cautionary

More information